

# Michael A Lawton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4032781/publications.pdf>

Version: 2024-02-01

50  
papers

1,895  
citations

257101

24  
h-index

276539

41  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2955  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying activities of daily living impairment in Parkinson's disease using the Functional Activities Questionnaire. <i>Neurological Sciences</i> , 2022, 43, 1047-1054.	0.9	2
2	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. <i>Brain</i> , 2022, 145, 584-595.	3.7	65
3	A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 617-624.	0.9	7
4	Combining biomarkers for prognostic modelling of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 707-715.	0.9	9
5	Testing shortened versions of smell tests to screen for hyposmia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A79.2-A79.	0.9	0
6	Exploration of whether socioeconomic factors affect the results of priority setting partnerships: updating the top 10 research priorities for the management of Parkinson's in an international setting. <i>BMJ Open</i> , 2022, 12, e049530.	0.8	2
7	Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 424-433.	2.2	101
8	Olfactory Testing in Parkinson Disease and REM Behavior Disorder. <i>Neurology</i> , 2021, 96, e2016-e2027.	1.5	12
9	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	1.5	56
10	Comparison between four published definitions of hyposmia in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e2258.	1.0	4
11	Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study. <i>Movement Disorders</i> , 2021, 36, 2821-2832.	2.2	24
12	Socio-Demographic and Psychosocial Predictors of Salivary Cortisol from Older Male Participants in the Speedwell Prospective Cohort Study. <i>Psychoneuroendocrinology</i> , 2021, 135, 105577.	1.3	0
13	Blood Biomarkers With Parkinson's Disease Clusters and Prognosis: The Oxford Discovery Cohort. <i>Movement Disorders</i> , 2020, 35, 279-287.	2.2	59
14	The association between pain and impulse control behaviours in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 53-55.	1.1	3
15	Cohort profile: the Oxford Parkinson's Disease Centre Discovery Cohort MRI substudy (OPDC-MRI). <i>BMJ Open</i> , 2020, 10, e034110.	0.8	11
16	Genome-Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor. <i>Movement Disorders</i> , 2020, 35, 705-707.	2.2	7
17	Reply to: Predictors of Motor Complications in Early Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 193-193.	2.2	0
18	Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 394-398.	0.8	11

#	ARTICLE	IF	CITATIONS
19	Predicting motor, cognitive & functional impairment in Parkinson's. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1498-1509.	1.7	35
20	Impulse control disorders in Parkinson disease and RBD. <i>Neurology</i> , 2019, 93, e675-e687.	1.5	44
21	Predictors of motor complications in early Parkinson's disease: A prospective cohort study. <i>Movement Disorders</i> , 2019, 34, 1174-1183.	2.2	47
22	Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. <i>Brain</i> , 2019, 142, 2828-2844.	3.7	62
23	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 55-61.	1.1	14
24	Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 251-260.	0.9	36
25	Features of <i>GBA</i> -associated Parkinson's disease at presentation in the UK <i>Tracking Parkinson's</i> study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 702-709.	0.9	103
26	Developing and validating Parkinson's disease subtypes and their motor and cognitive progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1279-1287.	0.9	116
27	Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD. <i>Neurology</i> , 2018, 91, e1528-e1538.	1.5	91
28	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 27-32.	1.1	77
29	The Diagnosis of Urinary Tract Infection in Young Children (DUTY) Study Clinical Rule: Economic Evaluation. <i>Value in Health</i> , 2017, 20, 556-566.	0.1	10
30	Personality and addictive behaviours in early Parkinson's disease and REM sleep behaviour disorder. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 72-78.	1.1	27
31	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. <i>Parkinsonism and Related Disorders</i> , 2017, 40, 40-46.	1.1	15
32	Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. <i>Sleep</i> , 2017, 40, .	0.6	138
33	Considerations in the Use of MDS Research Criteria for Prodromal Parkinson's in Rapid Eye Movement Sleep Behaviour Disorder and Population Cohorts. <i>Sleep</i> , 2017, 40, .	0.6	3
34	Comparison of microbiological diagnosis of urinary tract infection in young children by routine health service laboratories and a research laboratory: Diagnostic cohort study. <i>PLoS ONE</i> , 2017, 12, e0171113.	1.1	6
35	Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection. <i>Journal of Parkinson's Disease</i> , 2016, 6, 289-300.	1.5	21
36	Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1183-1190.	0.9	24

#	ARTICLE	IF	CITATIONS
37	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 96-101.	1.1	46
38	Improving the Diagnosis and Treatment of Urinary Tract Infection in Young Children in Primary Care: Results from the DUTY Prospective Diagnostic Cohort Study. <i>Annals of Family Medicine</i> , 2016, 14, 325-336.	0.9	29
39	Validation of conversion between mini-mental state examination and montreal cognitive assessment. <i>Movement Disorders</i> , 2016, 31, 593-596.	2.2	51
40	Nappy pad urine samples for investigation and treatment of UTI in young children: the "DUTY" prospective diagnostic cohort study. <i>British Journal of General Practice</i> , 2016, 66, e516-e524.	0.7	6
41	Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1518-1526.	2.2	128
42	The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness. <i>Health Technology Assessment</i> , 2016, 20, 1-294.	1.3	56
43	Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. <i>Health Technology Assessment</i> , 2016, 20, 1-48.	1.3	20
44	Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives. <i>Movement Disorders</i> , 2015, 30, 1759-1766.	2.2	54
45	Parkinson's Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort. <i>Journal of Parkinson's Disease</i> , 2015, 5, 269-279.	1.5	82
46	Tracking Parkinson's: Study Design and Baseline Patient Data. <i>Journal of Parkinson's Disease</i> , 2015, 5, 947-959.	1.5	64
47	A longitudinal model for disease progression was developed and applied to multiple sclerosis. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1355-1365.	2.4	20
48	Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. <i>Lancet Neurology</i> , The, 2015, 14, 497-505.	4.9	91
49	FEATURES IN IDIOPATHIC RBD MIRROR THOSE OBSERVED IN PD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.94-e4.	0.9	0
50	PARKINSON'S DISEASE: HOW MANY FORMS ARE THERE?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, e4.113-e4.	0.9	0